Middle East & Africa Ankylosing Spondylitis Market Size & Outlook
MEA ankylosing spondylitis market highlights
- The MEA ankylosing spondylitis market generated a revenue of USD 103.7 million in 2024.
- The market is expected to grow at a CAGR of 8.5% from 2025 to 2033.
- In terms of segment, non-steroidal anti-inflammatory drugs (nsaids) was the largest revenue generating drug class in 2024.
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is the most lucrative drug class segment registering the fastest growth during the forecast period.
MEA data book summary
| Market revenue in 2024 | USD 103.7 million |
| Market revenue in 2033 | USD 218.9 million |
| Growth rate | 8.5% (CAGR from 2025 to 2033) |
| Largest segment | Non-steroidal anti-inflammatory drugs (nsaids) |
| Fastest growing segment | Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) |
| Historical data covered | 2021 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) |
| Key market players worldwide | AbbVie Inc, Amgen Inc, Pfizer Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Johnson & Johnson, Merck & Co Inc |
Other key industry trends
- In terms of revenue, MEA region accounted for 1.6% of the global ankylosing spondylitis market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 2,124.1 million by 2033.
Key Regions: U.S. , UK , Japan , Brazil , South Africa
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Ankylosing Spondylitis Market Scope
Ankylosing Spondylitis Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Eli Lilly and Co | View profile | 43000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | https://www.lilly.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| UCB SA | View profile | 9083 | Allee de la Recherche, 60, Brussels, Belgium, B-1070 | https://www.ucb.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
| Amgen Inc | View profile | 26700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | https://www.amgen.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
Middle East & Africa ankylosing spondylitis market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to ankylosing spondylitis market will help companies and investors design strategic landscapes.
Non-steroidal anti-inflammatory drugs (nsaids) was the largest segment with a revenue share of 109.64% in 2024. Horizon Databook has segmented the Middle East & Africa ankylosing spondylitis market based on non-steroidal anti-inflammatory drugs (nsaids) covering the revenue growth of each sub-segment from 2021 to 2033.
- Middle East & Africa Ankylosing Spondylitis Drug Class Outlook (Revenue, USD Million, 2021-2033)
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- TNF Inhibitors
- Humira
- Simponi
- Remicade
- Enbrel
- Cimzia
- Other TNF Inhibitors
- Other Drug Classes
- Middle East & Africa Ankylosing Spondylitis Distribution Channel Outlook (Revenue, USD Million, 2021-2033)
- Hospital Pharmacy
- Retail Pharmacy
- Others
Reasons to subscribe to Middle East & Africa ankylosing spondylitis market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa ankylosing spondylitis market databook
-
Our clientele includes a mix of ankylosing spondylitis market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa ankylosing spondylitis market, including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa ankylosing spondylitis market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
